Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company through its wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI) announced today it has entered into an exclusive 5-year marketing and distribution agreement with Grifols USA, LLC. Under the terms of the agreement, Grifols USA, LLC will market and sell ADI's DR-70 Onko-Sure cancer test for the monitoring of colorectal cancer (CRC) to hospitals, clinical labs, clinics, and other healthcare organizations throughout the US.
Grifols is a publicly-traded, multinational healthcare products manufacturer and distributor. The company has business operations in more than 90 countries worldwide focused on the research and development, manufacturing, distribution, marketing, sales, and customer support for a diverse range of in-house and 3rd party healthcare products and services, now including ADI's DR-70 Onko-Sure cancer test.
The agreement is the latest milestone ADI has achieved in support of the company's aggressive commercialization strategy for Onko-Sure. According to the agreed upon terms, Grifols USA, LLC has the rights to market and distribute ADI's Onko-Sure cancer test specifically for the monitoring of colorectal cancer in the US. This includes developing and implementing a marketing strategy to drive product awareness; educate clinical laboratories and physicians; and generate product sales.
According to Patricia Silver, General Manager, US Diagnostic Division at Grifols USA, LLC, "We are intensely dedicated to providing hospitals, labs and clinics with highly innovative and in-demand products and services which improve the level and quality of patient health care around the world, and we are very pleased to support the commercialization of ADI's Onko-Sure cancer test in the US. ADI has developed a new option to assist physicians and their patients in monitoring the recurrence of cancer and we are excited to bring it to the marketplace."
"We are extremely pleased to announce a top-tier distribution partnership for our Onko-Sure cancer test in the USA," commented Mr. Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals & ADI. "We are making great progress on our commercialization plan for Onko-Sure(TM), and with this latest agreement, doing so with one of the most recognized, respected and experienced companies in the healthcare sector. We are dedicated to establishing a strong, long-lasting and highly successful relationship with the Grifols team - one that will help make Onko-Sure(TM) the standard in cancer testing and deliver direct value to our customers, patients, and shareholders."
Tiny DNA circles are key drivers of cancer formation, study suggests